Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 181, Issue 2, Pages 774-778Publisher
UNIV CHICAGO PRESS
DOI: 10.1086/315258
Keywords
-
Categories
Funding
- NIAID NIH HHS [AI-29549] Funding Source: Medline
- NIDDK NIH HHS [DK-51406] Funding Source: Medline
Ask authors/readers for more resources
Escherichia coli FimH adhesin mediates binding to the bladder mucosa. In mice, a FimH vaccine protects against bacterial challenge. In this study, 4 monkeys were inoculated with 100 mu g of FimCH adhesin-chaperone complex mixed with MF59 adjuvant, and 4 monkeys were given adjuvant only intramuscularly. After 2 doses (day 0 and week 4), a booster at 48 weeks elicited a strong IgG antibody response to FimH in the vaccinated monkeys, All 8 monkeys were challenged with 1 mL of 10(8) E. coli cystitis isolate NU14. Three of the 4 vaccinated monkeys were protected from bacteruria and pyuria; all control monkeys were infected. These findings suggest that a vaccine based on the FimH adhesin of E. coli type 1 pill may have utility in preventing cystitis in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available